Please login to the form below

Not currently logged in
Email:
Password:

heart failure therapy

This page shows the latest heart failure therapy news and features for those working in and with pharma, biotech and healthcare.

Pfizer pays $250m upfront to Akcea for phase 2 antisense drug

Pfizer pays $250m upfront to Akcea for phase 2 antisense drug

drugs. New therapies like Novartis’ heart failure therapy Entresto (sacubitril/valsartan) and cholesterol-lowering PCSK9 inhibitors from Amgen and Sanofi/Regeneron have re-injected growth into the market, although they have ... ANGPTL3 is a protein

Latest news

  • FDA fast-tracks AstraZeneca’s Farxiga in heart failure FDA fast-tracks AstraZeneca’s Farxiga in heart failure

    This study investigated Farxiga in heart failure patients with reduced ejection fraction (HFrEF). ... adults with both heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF).

  • AZ’s Farxiga heart failure results wow the ESC AZ’s Farxiga heart failure results wow the ESC

    Chases after market leader Jardiance. AstraZeneca has already revealed that the DAPA-HF trial of AstraZeneca’s diabetes therapy Farxiga in heart failure with reduced ejection fraction (HFrEF) was a win, ... non-diabetic population and make it an option

  • AZ unveils phase 3 Brilinta data in CAD and type 2 diabetes AZ unveils phase 3 Brilinta data in CAD and type 2 diabetes

    The observed patient population included patients with CAD and type 2 diabetes who had not previously had a heart attack or stroke. ... In addition to Brilinta, AZ presented the full results from its  DAPA-HF trial of its diabetes therapy Farxiga in

  • Blow for Entresto in latest heart failure trial Blow for Entresto in latest heart failure trial

    hospitalisations. The news is unfortunate for Novartis, as heart failure remains an area of high unmet need, affecting around 26 million people worldwide. ... Novartis has faced increasing competition in the heart failure therapy area of late, with

  • Novartis raises 2019 guidance as new products gather speed Novartis raises 2019 guidance as new products gather speed

    Topping the table once again is Novartis’s psoriasis drug Cosentyx (secukinumab), which grew 25% to $858m, with heart failure therapy Entresto (sacubitril/valsartan) rocketing 81% after being recommended for ... from new prostate cancer therapy

More from news
Approximately 0 fully matching, plus 41 partially matching documents found.

Latest Intelligence

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    CAR-T cell therapy for children with B-cell ALL. ... costs. It was then backed with a ‘no response-no payment’ contract. It has also struck novel reimbursement packages with its heart failure therapy Entresto and its psoriasis treatment Cosentyx.

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    the heart, and its proposed benefits have been backed up in clinical trials. ... failure by 18%  compared to placebo when given on top of standard HF therapy.

  • Pharma deals in April 2015 Pharma deals in April 2015

    uniQure has licensed its proprietary gene therapy programme for congestive heart failure, that is hoped will restore the heart's ability to synthesise S100A1, a calcium sensor and master regulator of ... to become available for common diseases such as

  • Pharma deals during October 2013 Pharma deals during October 2013

    heart failure (phase IIb). 75. ... 75. Trevena. TRV027, GPCR biased ligand for acute heart failure (phase II).

More from intelligence
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest appointments

  • uniQure appoints chief executive officer uniQure appoints chief executive officer

    Kapusta had previously served as the gene therapy specialist's interim chief executive since September last year, as well as chief financial officer since January 2015. ... for congestive heart failure and Huntington's disease into the clinic.”.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?
Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...

Infographics